To get the latest experience from our website, please upgrade your browser.
The FDA warned about potentially fatal side effects of Invokana and other SGLT2 inhibitor drugs. Invokana lawyers filed lawsuits on behalf of people who say they these drugs injured them. SGLT2 inhibitors treat Type 2 diabetes but may trigger dangerous levels of blood acids and increase the risk of urinary tract infections. Studies also show they may increase the risk of stroke, heart attack and kidney problems that may require hospitalization.
Invokana lawyers are actively accepting cases involving the development of ketoacidosis, kidney failure, urinary tract infections, heart attacks, strokes and the use of Invokana and Invokamet or other SGLT2 inhibitor.
Plaintiff's attorneys argue that drug manufacturers did not properly warn patients and doctors of the risks. If doctors or patients had known, they might have been more likely to choose another medication or had proper testing done to monitor their health.
People who feel Invokana or other SGLT2 inhibitor injured them or caused serious side effects may contact an attorney to protect their right to make a claim for compensation. An attorney can determine whether you have a case against one of the drug manufacturers.
Some of the claims made in similar lawsuits against drug companies accuse manufacturers of:
Other drugs in these lawsuits include:
A Georgia woman is suing Invokana maker Janssen Pharmaceuticals, alleging she developed diabetic ketoacidosis after consuming Invokana as prescribed by her physician. Paula Brazil’s doctor told her to take the medicine in October 2013 for treatment of Type 2 diabetes. Brazil of Dalton. Ga., lost weight, experienced nausea and repeatedly vomited, her federal lawsuit says. She was admitted to a local hospital in November 2013 and diagnosed with diabetic ketoacidosis. She alleges she will experience a lifetime of pain and suffering. Other suits allege wrongful-death claims. The family of Ida Mae Jones Jackson filed suit against Janssen in Louisiana. She suffered from ketoacidosis after taking the drug, according to the lawsuit. The disorder led to kidney damage, a heart attack and a stroke. Then she died. Their lawsuit claims Janssen and parent company Johnson & Johnson knew about the risks but withheld information from patients and doctors.
Because the lawsuits against Johnson & Johnson and Janssen Pharmaceuticals are ongoing, drug companies have not yet offered any settlements. There are also no trials scheduled at this time. Other SGLT2 inhibitor lawsuits are also still pending.
There is still time to file an Invokana lawsuit for any injuries that the FDA and clinical studies link to the drug. But, there is a limited time to file a claim because each state has a time limit called a statute of limitations (SOL). An Invokana lawyer can help you determine if filing a lawsuit is right for you.
THE FDA WARNING RECOMMENDS PEOPLE TAKING AN SGLT2 INHIBITOR LOOK FOR SYMPTOMS OF KETOACIDOSIS. SYMPTOMS INCLUDE:
Ketoacidosis is not the only troubling side effect of Invokana and other SGLT2s that may lead to hospitalization or death in extreme cases. The FDA approved Invokana with the condition that Johnson & Johnson conduct several safety studies and a clinical trial showing that the drug did not increase the risk of cardiovascular problems.
In 2013, the FDA panel convened to review initial data on the drug. They found that the medication increased the risk of stroke by 46 percent in people who took Invokana versus those who took a placebo. Dr. Mat Stroup, an FDA biostatistician, elaborated on available data and said patients who took Invokana had a 690 percent higher risk for cardiovascular events than patients show did not take the drug. Some plaintiff filed lawsuits after suffering heart attacks or strokes they say Invokana caused.
On top of the FDA warnings, experts have more concerns about Invokana. The Institute for Safe Medication Practices (ISMP)'s May 6, 2015, edition of Quarter Watch warns the FDA received a number of adverse reactions linked to the drug. According to the agency, adverse effects linked to this drug were higher than 92 percent of all the drugs the healthcare group monitored.
In the first year after Invokana hit the market, the agency received more than 450 serious adverse event reports. Many of these reports involved renal toxicity: